RIBOMUSTIN

This brand name is authorized in Australia, Brazil, Ecuador, Israel, New Zealand, South Africa

Active ingredients

The drug RIBOMUSTIN contains one active pharmaceutical ingredient (API):

1 Bendamustine UNII 981Y8SX18M - BENDAMUSTINE HYDROCHLORIDE

Bendamustine is an alkylating antitumour agent with unique activity. The antineoplastic and cytocidal effect of bendamustine is based essentially on a cross-linking of DNA single and double strands by alkylation. As a result, DNA matrix functions and DNA synthesis and repair are impaired. Read about Bendamustine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RIBOMUSTIN Powder for solution for infusion	Marketing Authorisation Holder	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01AA09	Bendamustine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01A Alkylating agents → L01AA Nitrogen mustard analogues
Discover more medicines within L01AA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10760H, 10763L
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 514517090033302, 514517090033402
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): H6210713
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7666, 7674, 7675
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 16049, 16050
Country: ZA	Health Products Regulatory Authority	Identifier(s): 45/26/1127, 45/26/1128